Atosiban
Atosiban, Tractocile (atosiban) is a protein pharmaceutical. Atosiban was first approved as Tractocile on 2000-01-20. It has been approved in Europe to treat premature birth. It is known to target vasopressin V1b receptor, vasopressin V1a receptor, oxytocin receptor, and vasopressin V2 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Premature obstetric labor | D007752 | — | O60 | — | 2 | 4 | 1 | — | 7 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | 2 | 2 | 1 | 2 | 7 |
| Infertility | D007246 | HP_0000789 | — | — | — | — | 1 | 1 | 2 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometriosis | D004715 | EFO_0001065 | N80 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Meningomyelocele | D008591 | EFO_1001369 | Q05 | — | — | — | — | 1 | 1 |
| Spina bifida cystica | D016137 | — | Q05 | — | — | — | — | 1 | 1 |
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Female infertility | D007247 | EFO_0008560 | N97 | — | — | — | — | 1 | 1 |
| Cervical cerclage | D023802 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Atosiban |
| INN | atosiban |
| Description | Atosiban, sold under the brand name Tractocile among others, is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. It was developed by Ferring Pharmaceuticals in Sweden and first reported in the literature in 1985. Originally marketed by Ferring Pharmaceuticals, it is licensed in proprietary and generic forms for the delay of imminent preterm birth in pregnant adult women.
|
| Classification | Protein |
| Drug class | oxytocin antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC2=O)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 90779-69-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL382301 |
| ChEBI ID | — |
| PubChem CID | 5311010 |
| DrugBank | DB09059 |
| UNII ID | 081D12SI0Z (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
AVPR1B
AVPR1B
AVPR1A
AVPR1A
OXTR
OXTR
AVPR2
AVPR2
Organism
Homo sapiens
Gene name
AVPR1B
Gene synonyms
AVPR3, VPR3
NCBI Gene ID
Protein name
vasopressin V1b receptor
Protein synonyms
Antidiuretic hormone receptor 1b, arginine vasopressin receptor 3, AVPR V1b, AVPR V3, pituitary vasopressin receptor 3, V1B receptor, Vasopressin V3 receptor
Uniprot ID
Mouse ortholog
Avpr1b (26361)
vasopressin V1b receptor (Q9WU02)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,026 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
607 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use